Supervisor : Dr David Kryza Dr Clément Morgat

Title : new radiopharmaceuticals for targeted radionuclide therapy

Keywords: radiopharmaceuticals, cancer, imaging, therapy, in vivo studies

Starting date: sept/oct-23

Laboratory: the LAGEPP is a research laboratory of the University Lyon 1 and the French National Institute for Scientific research (CNRS UMR 5007). It develops multidisciplinary research in chemical engineering, pharmaceutical engineering and biochemical processes. The imaging plat-form Imthernat has a strong expertise notably for in vivo biodistribution and efficacy studies in mice models using SPECT/CT, PET/CT and Cerenkov imaging.

The post doctoral researcher will take part of a French jointed project aiming at evaluating novel radiopharmaceuticals for imaging and therapy of selected cancers including hard-to-treat cancer models (triple negative breast cancer, glioblastoma, pancreatic adenocarcinoma, etc)

Principal activities

  • Generation and follow-up of xenografted mice
  • Radiolabeling
  • In vivo imaging and biodistribution
  • Image analysis and data processing

Required skills

  • Use of preclinical cancer models
  • Cell culture
  • In vivo animal experience

Soft skills

  • Motivated,
  • Enthusiastic
  • Strong commitment for the research project
  • Good communication, presentation and writing skills
  • Able to lead work
  • Good sense for initiative and quality
  • Team player

Language: English is required. French is optional

The application must include

  • CV
  • Motivation letter
  • Two reference letters
  • Academic works that you would like to be considered in the assessment

 

Contacts: david.kryza@univ-lyon1.fr; clement.morgat@u-bordeaux.fr